

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) An isolated polypeptide comprising a sequence selected from one of:

(a) SEQ ID NOS:1-23; or

(b) SEQ ID NOS:26-31.

2. (Canceled).

3. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:1 or SEQ ID NO:9.

4. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:2 or SEQ ID NO:10.

5. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:3 or SEQ ID NO:7.

6. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:8.

7. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:4 or SEQ ID NO:13.

8. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:5 or SEQ ID NO:17.

9. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:6 or SEQ ID NO:18.

10. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:12 or SEQ ID NO:21.

11. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:11 or SEQ ID NO:15.

12. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:14 or SEQ ID NO:16.

13. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:19 or SEQ ID NO:20.

14. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:22 or SEQ ID NO:23.

15. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:26 or SEQ ID NO:27.

16. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:28 or SEQ ID NO:29.

17. (Original) The isolated polypeptide of claim 1 wherein the sequence is selected from SEQ ID NO:30 or SEQ ID NO:31.

18. (Previously Presented) The isolated polypeptide of claim 1 wherein the polypeptide comprises part of a carrier protein.

19. (Previously Presented) The isolated polypeptide of claim 1 further comprising an accessory molecule.

20. (Previously Presented) The isolated polypeptide of claim 19 wherein the accessory molecule is a tag molecule, chemotherapeutic agent, radiopharmaceutical, cytotoxic agent, treatment molecule, antigenic molecule, antibody fragment or antibody.

21. (Previously Presented) The isolated polypeptide of claim 1 wherein the polypeptide consists essentially of a sequence selected from (a) or (b).

22 - 32. (Canceled).

33. (Previously Presented) A kit comprising one or more polypeptides comprising a sequence selected from one of:

(a) SEQ ID NOS:1-23; or

(b) SEQ ID NOS:26-31.

34 - 54. (Canceled).

55. (Currently Amended) An isolated polypeptide comprising a sequence selected from one of: SEQ ID NOS: ~~1-23~~ 1, 2, 3, 16 and 22 having one or more conservative amino acid substitutions, wherein the polypeptide binds to acute myeloid leukemia cells and further wherein the polypeptide induces differentiation of acute myeloid leukemia cells into mature blood cells.

56. (Currently Amended) The isolated polypeptide of claim 55 wherein the one or more conservative amino acid substitutions substitutes one hydrophobic residue for another hydrophobic residue.

57. (Previously Presented) The isolated polypeptide of claim 56 wherein the hydrophobic residues are independently selected from the group consisting of isoleucine, valine, leucine and methionine.

58. (Previously Presented) The isolated polypeptide of claim 56 wherein the hydrophobic residues are independently selected from the group consisting of phenylalanine or tryptophan.

59. (Previously Presented) The isolated polypeptide of claim 55 wherein the conservative amino acid substitution substitutes one polar residue for another.

60. (Previously Presented) The isolated polypeptide of claim 59 wherein the polar residues are independently selected from the group consisting of arginine and lysine.

61. (Previously Presented) The isolated polypeptide of claim 59 wherein the polar residues are independently selected from the group consisting of glutamic and aspartic acids.

62. (Previously Presented) The isolated polypeptide of claim 59 wherein the polar residues are independently selected from the group consisting of glutamine and asparagine.

63-72. (Canceled)

73. (Currently Amended) The isolated polypeptide of claim 55 wherein the sequence is ~~selected from SEQ ID NO:1 or SEQ ID NO:9~~ having one or more conservative amino acid substitutions.

74. (Currently Amended) The isolated polypeptide of claim 55 wherein the sequence is ~~selected from SEQ ID NO:2 or SEQ ID NO:10~~ having one or more conservative amino acid substitutions.

75. (Currently Amended) The isolated polypeptide of claim 55 wherein the sequence is ~~selected from SEQ ID NO:3 or SEQ ID NO:7~~ having one or more conservative amino acid substitutions.

76-81. (Cancelled)

82. (Currently Amended) The isolated polypeptide of claim 55 wherein the sequence is ~~selected from SEQ ID NO:14 or SEQ ID NO:16~~ having one or more conservative amino acid substitutions.

83-84. (Cancelled)

85. (Currently Amended) The isolated polypeptide of claim 55 wherein the sequence is ~~selected from SEQ ID NO: 22 or SEQ ID NO:23~~ having one or more conservative amino acid substitutions.

86-87. (Cancelled)

88. (Currently Amended) An isolated polypeptide comprising a sequence selected from one of SEQ ID NOS: 26-2331 having one or more conservative amino acid substitutions, wherein the polypeptide binds to normal bone marrow cells, but not to acute myeloid leukemia cells.

89. (Currently Amended) The isolated polypeptide of claim 88 wherein the sequence is selected from SEQ ID NO: 28 or SEQ ID NO: 29 having one or more conservative amino acid substitutions.

90. (Currently Amended) The isolated polypeptide of claim 88 wherein the sequence is selected from SEQ ID NO: 30 or SEQ ID NO: 31 having one or more conservative amino acid substitutions.

91. (New) The isolated polypeptide of claim 88 wherein the selected sequence has only one conservative amino acid substitution.

92. (New) The isolated polypeptide of claim 55 wherein the selected sequence has only one conservative amino acid substitution.

93. (New) An isolated polypeptide comprising a sequence selected from one of: SEQ ID NOS:13, 15 and 21 having one or more conservative amino acid substitutions, wherein the polypeptide binds to acute myeloid leukemia cells and further wherein the polypeptide induces differentiation of bone marrow cells obtained from a patient with acute myeloid leukemia.

94. (New) The isolated polypeptide of claim 93 wherein the selected sequence has only one conservative amino acid substitution.

95. (New) The isolated polypeptide of claim 93 wherein the sequence is SEQ ID NO:15 having one or more conservative amino acid substitutions.

96. (New) The isolated polypeptide of claim 93 wherein the sequence is SEQ ID NO:13 having one or more conservative amino acid substitutions.

97. (New) The isolated polypeptide of claim 93 wherein the sequence is SEQ ID NO:21 having one or more conservative amino acid substitutions.

98. (New) The isolated polypeptide of claim 82 wherein the polypeptide does not bind to normal bone marrow cells.

99. (New) An isolated polypeptide comprising amino acid sequence SEQ ID NO:16 having one or more conservative amino acid substitutions, wherein the polypeptide binds to acute myeloid leukemia cells but not to normal bone marrow cells.